medigraphic.com

2021, Number 3

<< Back Next >>

Rev Elec Psic Izt 2021; 24 (3)

The most frequent symptomathologies in women during climateric syndrome

López SRG, Chacón PWL

Language: Spanish
References: 27
Page: 1277-1290
PDF size: 373.40 Kb.


ABSTRACT

The climateric syndrome, is a health problem that demands the care of middle-aged women, is associated with a decrease in the quality of life, and the increase in the costs associated with their care. The prevalence of symptoms in Latin America ranges from 22% to 63%, and in Mexico 80% have symptoms but only one fifth have any treatment. The objective is to determine the most frequent symptomatology in women between 40 and 59 years of age in the Family Medicine Unit 80. Descriptive type study of cross-sectional design, 123 women with climatic symptoms were evaluated, sociodemographic and family variables were recorded. We applied the MRS questionnaire (Menopause Rating Scale) standardized instrument composed of 11 items that make up 3 symptomatic domains: somatic, psychological and urogenital. Registration Ethics- Research Committee:2019-1602-031. The analysis was performed in SPSS V25 using descriptive statistics, and the results were expressed in simple frequencies and percentage distribution. The 5 most frequently found symptoms in the climate stage were hot flashes, sweating and heat (74%), vaginal dryness (68%), urinary problems (62%), anxiety (62%) and irritability (58%). The severity of the climatic symptomatology was 80% with severe symptoms and 20% very severe intensity. The present study concludes that the most affected domain at the climacteric stage was somatic, followed by psychological and finally urogenital.


REFERENCES

  1. Basavilvazo RodriguezMA, Fuentes Morales S, Puello Tamara ER, Torres Arreola LP, Orozco Vazquez G, Bedia Sanchez LM, et al. Guia de práctica clínica, atención del climaterio y menopausia. Evidencias y recomendaciones, Mexico: Secretaria de Salud; 2009 (citado 6 de May 2012).

  2. Freedman R. (2005). Hot flashes: behavioral treatments, mechanisms. And relation to sleep. Am J Med 2005; 118:124S-130S.

  3. Freeman E. (2007). Sheriff K. prevalence of hot flushes and night sweats around the world: a systematic review. Climateric 2007;10:197-214.

  4. Palacios S. et al. Age of menopause and impact of climateric symptoms by geographical región. Climateric 2010; 13(5): 419-428.

  5. Makara-Studzinska MT, Krys-Noszczyk KM, Jakiel G. epidemiology of the symptoms of menopause – an intercontinental review. Prz Menopauzaln. 2014; 13(3): 203-211.

  6. COMEGO. Estudio del climaterio y la menopausia. COMEGO. 2010.

  7. Santiago Alba S. atención integral a las mujeres de edad mediana. Rv Cubana Obstet Ginecol, 2011;37(2):251-70.

  8. Asociación Guatemalteca de Climaterio Y menopausia. Guía de practica de manejo de la mujer climatérica. REVCOG. 2009;14(1):24-31. Gonzales GE, CARILLO C. Blood serotonin levels in postmenopausal women: effects of age and serum estradiol levels. Maturitas 1993; 17: 23-9.

  9. FINK G. SUMMER BEH. Oestrogen and mental state. Nature 1996; 383: 306.

  10. Gudelski G, Koenig J, Meltzer H. Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Neuropharmacology 1986; 25: 1307-13.

  11. Mazzola-Pomietto P, Aulakh C, Wozniak K, Hill J, Maurphy D. Evidence that 1- (2,5-dimethoxy-4-iodophenyl)-2-aminopropane of 5-HT2A receptors. Psychopharmacology 1995; 117: 193-9.

  12. Vargas-Hernandez VM, Acosta-Altamirano G, Moreno-Eutimio MA, Vargas-Aguilar VM, Flores_barrios K, Tovar-Rodriguez JM. Terapia hormonal de reemplazo durante la menopausia. Rev Hosp Juarez Mex. 2013;80(4):251-61.

  13. Williams RE, Kalilani L, Bibenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008;11:32-43.

  14. Porcile A, Aedo S, Hernandez Y. fundamentos del uso de estrógenos en dosis bajas con progestina periódica en TRH oral para mujeres posmenopáusicas. Rev Chil Obstet Ginecol 2003; 68(5): 430-8.

  15. Soares Cn, Almeida Op, Joffe H Y Cohen Ls, Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: A doublé-blind, randomized, placebo controlled trial. Archive of General Psychiatry 2001; 58(6): 529-34.

  16. Aedo S, Bl, Mel J, Rojas C, Cabrera M, Campodonico I. (2012). Análisis de constructo de la escala MRS versión chilena. Rev Obstet Ginecol Hosp. Santiago Oriente Dr. Luis Tisné Brousse, 2012; en prensa.

  17. Gonzalez.Merlo J, Gonzalez E. Ginecologia. España: Elseiver, 9 ed. 2014. P.94- 118.

  18. Carranza S. introducción a la endocrinología ginecológica. Mexico: Trillas, 1 ed. 2011.

  19. IMSS. Guía de practica clínica, diagnostico y tratamiento de la perimenopausia y postmenopausia. Mexico; 2013.

  20. Aedo S, Porcile A, Irribarra C. Calidad de vida relacionada con el climaterio en una población Chilena de mujeres saludables. Rev Chil Obstet Ginecol. 2006; 71:402-9.

  21. Heinemann K, Ruebing A Potthoff P, Schneider HP, Strelow F, Heinemann LA, al, The Menopause Rating Scale (MRS); a methodological review. Health qual life Outcomes. 2004;2:45. DOI: 10,1186/1477-7525-2-45.

  22. E.A. Cruz Martinez, V. Cruz Anguiano, J. Martinez Torres, D. Boo Vera.calidad de vida en mujeres durante su climaterio. Revista de la facultad de Medicina de la UNAM, Vol, 55, N 4, Julio-Agosto 2012.

  23. Alvaro Monterrosa-Castro, Angel Jose Paternina-Caicedo, Edwin Herazo_Acevedo, Heidi Celina Oviedo-Acevedo, Adalberto Campo-Arias. Utilidad del Menopause Rating Scale (MRS) en Indigenas Colombianas en Climaterio. Revista Duazary, Enero . Junio de 2017, vol. 14 n.1.

  24. Monica del Prado A, Andrea Fuenzalida, Daniela Jara, Rodrigo Figueroa J, Daniel Flores, Juan E blumel M2. Evaluacion de la calidad de vida en mujeres de 40 a 59 años mediante la escala MRS (Menopause Rating Scale). Rev Med Chile 2008; 136: 1511-7.

  25. Socheg, Anexo N 3. Instrumento ORAI para decidir densitometria. Disponible en: http://www.socheg.cl/Anexo%20ORAI.pdf.Diciembre 18, 2017.

  26. Aedo S, Cavada G, Blumel JE, Chedraui P, Fica J, Bariga P, et al. (2015). Women´sHealth Initiative estrogen plus progestin clinical trial: a study thatdoes not allow establishing relevant clinical risks. Menopause. 2015;22:1317-22. DOI: 10.1097/gme.0000000000000472.

  27. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. the effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids,and lipoproteins in healthy postmenopausal women. Menopause. 2006;13:643-50.




2020     |     www.medigraphic.com